Philippa Flint has more than 11 years of experience in drug development and regulatory affairs at big pharma, combined with 10 years of capital markets experience as an equity research analyst. Prior to becoming Princial of Private Debt at CPP Investment Board she was working at Bloom Burton & Co. Flint and previously was an equity analyst at RBC Dominion Securities, providing research coverage of small- to mid-cap biotech/pharma companies. She has been consistently ranked the top earnings estimator in Canada in the healthcare sector by StarMine, including over the period from 2004-2008 and in 2011. Prior to this, Flint was the vice president for medical affairs at AstraZeneca Canada, managing a department of 150 people working on more than 100 clinical trials. She led the merger of Astra and Zeneca in Canada, prior to which she was the vice president for regulatory affairs and corporate project management at Astra Canada. Flint holds master's of science degree and a master's degree in business administration.